Wednesday, May 6, 2020
REGISTRATION & CONTINENTAL BREAKFAST
7:00 - 8:00  
WELCOME
8:00 - 8:15

Welcome and Introduction to the Programme

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada


William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada


Overview of Today’s Sessions

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

SESSION 1:
Mutations, variants, databases
8:15 - 9:45

CHAIR: Lawrence Brody, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

8:15 - 8:35

Variant interpretation in the genomic era

Jonathan Berg, MD, UNC School of Medicine, Chapel Hill, NC, USA

8:35 - 8:55

Functional classification of HRD gene variant using CRISPR screens

Lea Starita, PhD, University of Washington, Seattle, WA, USA

8:55 - 9:05

Proffered paper 1

9:05 - 9:15

Proffered paper 2

9:15 - 9:25

Proffered paper 3

9:25 - 9:45

Question and discussion period (all speakers)

BREAK
9:45 - 10:15  
SESSION 2:
Pathology – Clinical relevance
10:15 - 11:45

CHAIR: Blaise Clarke, MD, University Health Network, Toronto, ON, Canada

10:15 - 10:35

Breast cancer susceptibility genes, pathology and outcome

Marjanka Schmidt, PhD, Netherlands Cancer Institute, Amsterdam, and Leiden University Medical Center, Leiden, The Netherlands

10:35 - 10:55

Where do ovarian cancers originate and why does it matter?

Christopher Crum, MD, Brigham and Women's Hospital, Boston, MA, USA

10:55 - 11:05

Proffered paper 1

11:05 - 11:15

Proffered paper 2

11:15 - 11:25

Proffered paper 3

11:25 - 11:45

Question and discussion period (all speakers)

LUNCH

11:45 - 13:15  

Optional Sponsored Symposium (TBD)

11:45 - 13:15  

SESSION 3:
Applied functional and computational genetics
13:15 - 14:45

CHAIR: Britta Weigelt, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

13:15 - 13:35

Mutational profiles - New approaches to genetic diagnosis and treatment

Serena Nik-Zainal, MD, PhD, University of Cambridge, Cambridge, UK

13:35 - 13:55

DNA Repair – Clinical relevance for breast cancer/ovarian cancer

Ralph Scully, MBBS, PhD, Beth Israel Deaconess Medical Center, Boston, MA, USA

13:55 - 14:05

Proffered paper 1

14:05 - 14:15

Proffered paper 2

14:15 - 14:25

Proffered paper 3

14:25 - 14:45

Question and discussion period (all speakers)

POSTER SESSION 1
    (with break)
14:45 - 16:30
SESSION 4:
Special Round Table: Population-based approaches to genetic testing and risk assessment – Beyond the current models
16:30 - 18:00

MODERATORS: Lawrence Brody, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA; and Clare Turnbull, MD, PhD, MFPH, Institute of Cancer Research, London, UK

INTRO, OVERVIEW, CONSIDERATIONS

Paul Pharoah, BM, BCh, PhD, University of Cambridge, Cambridge, UK

POPULATION TESTING

Integrated service provider program: the Geisinger experience

Adam Buchanan, MS, MPH, LGC, Genomic Medicine Institute, Geisinger Health System, Danville, PA, USA

National approaches: USA and beyond

Stephen Chanock¸ MD, National Cancer Institute, Rockville, MD, USA

Founder testing – the Israel approach: Is it generalizable?

Ephrat Levy-Lahad, MD, Shaare Zedek Medical Center, Jerusalem, Israel